Insulin extracellular space effect

In addition to the normal metabolic and elimination systems, circulating antibodies against insulin have important effects on its pharmacokinetic properties. Such antibodies may delay the exit of insulin from the vascular space to the extracellular interstitial space, where it exerts its actions. The insulin-antibody complex may also be cleared by the reticuloendothelial system, leading to an increased requirement of insulin. In general, insulin antibodies delay the onset of action of rapidly acting insulin and increase the duration of action of all insulins. 

Patients with acute hyperkalemia usually require other therapies to manage hyperkalemia until dialysis can be initiated. Patients who present with cardiac abnormalities caused by hyperkalemia should receive calcium gluconate or chloride (1 g intravenously) to reverse the cardiac effects. Temporary measures can be employed to shift extracellular potassium into the intracellular compartment to stabilize cellular membrane effects of excessive serum potassium levels. Such measures include the use of regular insulin (5 to 10 units intravenously) and dextrose (5% to 50% intravenously), or nebulized albuterol (10 to 20 mg). Sodium bicarbonate should not be used to shift extracellular potassium intracellularly in patients with CKD unless severe metabolic acidosis (pH less than 7.2) is present. These measures will decrease serum potassium levels within 30 to 60 minutes after treatment, but potassium must still be removed from the body. Shifting potassium to the intracellular compartment, however, decreases potassium removal by dialysis. Often, multiple dialysis sessions are required to remove potassium that is redistributed from the intracellular space back into the serum. 

---